Bonness Enterprises Inc. Sells 200 Shares of Johnson & Johnson (NYSE:JNJ)

Bonness Enterprises Inc. decreased its position in shares of Johnson & Johnson (NYSE:JNJFree Report) by 0.5% during the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 38,638 shares of the company’s stock after selling 200 shares during the period. Johnson & Johnson makes up about 2.2% of Bonness Enterprises Inc.’s investment portfolio, making the stock its 9th biggest position. Bonness Enterprises Inc.’s holdings in Johnson & Johnson were worth $6,112,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Keener Financial Planning LLC bought a new stake in shares of Johnson & Johnson in the fourth quarter worth $40,000. WFA Asset Management Corp lifted its position in shares of Johnson & Johnson by 61.4% during the fourth quarter. WFA Asset Management Corp now owns 255 shares of the company’s stock worth $40,000 after purchasing an additional 97 shares during the last quarter. Vermillion & White Wealth Management Group LLC acquired a new position in Johnson & Johnson in the fourth quarter worth about $44,000. Disciplined Equity Management Inc. acquired a new stake in Johnson & Johnson during the fourth quarter valued at approximately $45,000. Finally, Grayhawk Investment Strategies Inc. lifted its holdings in Johnson & Johnson by 528.6% during the 4th quarter. Grayhawk Investment Strategies Inc. now owns 308 shares of the company’s stock worth $48,000 after buying an additional 259 shares during the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms recently issued reports on JNJ. Morgan Stanley dropped their price target on Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating on the stock in a research report on Wednesday, April 17th. StockNews.com lowered shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a report on Saturday. Royal Bank of Canada reiterated an “outperform” rating and set a $175.00 price objective on shares of Johnson & Johnson in a research note on Monday, June 17th. HSBC upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and lifted their target price for the company from $169.00 to $170.00 in a research note on Thursday, April 18th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a report on Thursday, June 20th. Eight equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, Johnson & Johnson presently has an average rating of “Hold” and a consensus target price of $174.07.

Check Out Our Latest Analysis on Johnson & Johnson

Johnson & Johnson Price Performance

Shares of JNJ stock traded down $1.02 during midday trading on Tuesday, reaching $148.10. 1,298,610 shares of the company were exchanged, compared to its average volume of 7,382,136. The company’s 50 day moving average price is $148.08 and its two-hundred day moving average price is $154.29. The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.94 and a current ratio of 1.17. The company has a market cap of $356.43 billion, a P/E ratio of 9.27, a PEG ratio of 2.47 and a beta of 0.53. Johnson & Johnson has a 12 month low of $143.13 and a 12 month high of $175.97.

Johnson & Johnson (NYSE:JNJGet Free Report) last released its earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, topping analysts’ consensus estimates of $2.64 by $0.07. Johnson & Johnson had a return on equity of 36.70% and a net margin of 45.26%. The firm had revenue of $21.38 billion during the quarter, compared to the consensus estimate of $21.39 billion. During the same period in the prior year, the firm posted $2.68 earnings per share. The firm’s revenue for the quarter was up 2.3% compared to the same quarter last year. On average, sell-side analysts expect that Johnson & Johnson will post 10.63 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 4th. Shareholders of record on Tuesday, May 21st were given a $1.24 dividend. The ex-dividend date of this dividend was Monday, May 20th. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.19. This represents a $4.96 annualized dividend and a yield of 3.35%. Johnson & Johnson’s payout ratio is 30.92%.

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

Featured Articles

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJFree Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.